Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Oruka Therapeutics $700 million follow-on offering
We advised Oruka on the offering
GH Research $117.5 million follow-on offering
We advised GH Research on the offering
Avalyn Pharma $300 million IPO
We advised the underwriters on the IPO
Mabwell Bioscience HK$1.2 billion IPO
We advised Mabwell on its IPO and HKEX listing
Maze Therapeutics $150 million offering
We advised the sole underwriter on the offering
McKesson sale of minority stake in Medical-Surgical Solutions to Apollo
We are advising McKesson on the transaction
JATT II Acquisition $60 million SPAC IPO
We advised the sole bookrunning manager in connection with the IPO
Revolution Medicines $2.2 billion common stock and convertible notes offerings
We advised the underwriters on the concurrent offerings
Adagene $70 million registered direct offering
We advised Adagene on the offering
AN2 Therapeutics $80 million at-the-market offering
We advised the sales agent on the offering